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ABSTRACT 
Computer Systems Validation (CSV) is a process used to ensure (and document) that a computer based systems will produce information or 
data that meet a set of defined requirements. If a system meets these requirements, it can be assumed that it is consistently performing in 
the way it was intended. Quality is an imperative for customers whenever they consider a product or service. It is also important as it relates 
to life-saving products such as pharmaceuticals. In this regard, the Food and Drug Administration introduced good manufacturing practice 
(GMP) to maintain and improve the quality of pharmaceutical products. GMP ensures that products are consistently produced and controlled 
according to the quality standards appropriate to the intended use and as required by the marketing authorization. One of the major GMP 
requirements is that all of the critical manufacturing equipment, utilities, and facilities in the pharmaceutical industries must be properly 
qualified and validated prior to production. Currently, this practice forms the core of the regulations that are strictly followed by 
pharmaceutical companies worldwide.  A validation assessment program is a necessity in the pharma industry to ensure adherence to 
pharmaceutical cGMP guidelines, and to help companies maintain consistent quality. The same principles are applied in computer system 
validation to a computer system or an information technology system. It’s essential to maintain quality  standards in pharma since non-
conformance can have far-reaching consequences. Computer system validation checks the effectiveness and the efficiency with which the 
system is meeting the purpose for which it was designed. This study aims to identify needs of computer system validation of 
instrument/equipment practiced in the perspective of pharmaceutical industry. 
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INTRODUCTION 
The concept of validation was first proposed by Ted Byers 
and Bud Loftus in the mid-1970s to improve the quality of 
pharmaceutical products 1. Currently, in the 
pharmaceutical manufacturing industry, validation plays a 
vital role in producing high-quality pharmaceutical 
products that meet good manufacturing practice (GMP) 
guidelines. Validation is an important requirement 
imposed by authorities worldwide to regulate the 
production of pharmaceutical and medical devices. An 
equipment, utility, or facility that is not validated may 
produce inferior outputs 2. Thus, the Food and Drug 
Administration (FDA) requires validation, which is defined 
as the process of collecting and evaluating data to draw 
scientific evidence that an equipment, utility, or facility is 
capable of consistently delivering quality products. On the 
one hand, validation involves confirmation by examination 
and provision of objective evidence that the particular 
requirements for a specific intended use are fulfilled3. In 
the pharmaceutical concept, validation refers to the 
establishment of documented evidence that an equipment, 
utility, or system, when operated within established 
parameters, can perform effectively in producing a 
medicinal product that meets the predetermined 
specifications. Validation of software and computer 
systems follows the same principle as the qualification of 
instrument hardware. USP <1058> has a short chapter on 
software validation. Software is divided into three 
categories 
1. Firmware integrated as chips into instrument hardware 
for control through local user interface. 
2. Software for instrument control, data acquisition, and 
data processing. An example would be a chromatography 
data system. 
3. Standalone software, for example a Laboratory 
Information Management System (LIMS) package.  
Most valuable is the statement about firmware: “Firmware 
is considered as a component of hardware of the 
instrument itself. Indeed the qualification of hardware is 
not possible without operating its firmware. Thus when 
the hardware is qualified at the user’s site, the integrated 
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firmware is also essentially qualified. No separate on-site 
qualification of the firmware is needed.”4 
NEED OF VALIDATION, QUALIFICATION AND IT 
SYSTEM VALIDATION 
Pharmaceutical facilities consist of various processes, each 
of which must be accurate to ensure that the end product is 
of high quality. While validation is concerned mainly with 
processes, it is referred to as a qualification when the same 
approach is applied to a machine or equipment instead of a 
process5. 
Validation is a systematic approach where it is confirmed 
that any process in a pharmaceutical facility will operate 
within the specified parameters whenever required. This is 
achieved by collecting and analyzing data. Validation is 
done to assure that the processes will produce consistent 
and repeatable results within the predetermined 
specifications. Validation is needed as it verifies whether 
the quality standards and compliance are being met by the 
product in real time, which is really important in every 
pharmaceutical facility. Further, it also establishes that the 
facility is meeting current good manufacturing practice 
(cGMP) guidelines that are set for the industry by 
concerned regulatory bodies. Validation can be considered 
as a documented evidence of the process meeting the 
predetermined specifications. 
No pharmaceutical plant is complete without an IT system, 
which is responsible for controlling, supporting and 
documenting various processes. It is extremely important 
to validate the computer and IT systems as it makes sure 
that all the concerned IT applications are fulfilling their 
intended purposes. Validation helps in controlling different 
phases of development, design, testing and routine of the 
software that is being used by the IT system during its life 
cycle. As long as the computer system is running 
accurately, you can be assured that all the information and 
reports that they store remain safe. You must implement 
stringent quality requirements in GMP-regulated 
industries to control the procedures throughout the 
Software Development Life Cycle (SDLC). Focus the 
validation efforts on crucial aspects such as risk analysis 
and in-depth validation approach. Make sure that you 
apply the documentation to the computerized system as it 
manages crucial data that has an impact on the quality of 
the products. The components of computer system 
validation include all the activities that are involved in 
applying the appropriate controls throughout the SDLC 
and for procedures that are necessary for creating the 
documentation 6-8. 
ANALYTICAL INSTRUMENT QUALIFICATION & 
IMPORTANT OF CALIBRATION 
Before you conduct validation, you must complete the 
process of qualification. It is a systematic process that 
starts by the project phases of the installations, equipment 
and utilities. Analytical Instrumentation Qualification, also 
known as AIQ, is the documented process where a complex 
and sophisticated measurement device is demonstrated to 
be accurate, precise and selective enough for the intended 
analytical measurement. This is carried out to determine 
the sustainability and qualification of any instrument for 
the intended purpose. Qualification is not limited to a 
validation process, but it is a part of it. It can be further 
divided into installation qualification (IQ), operation 
qualification (OQ) or performance qualification (PQ). 
Based on the operation and function of equipment, system 
or utility, you must make installation qualification and 
operation necessary. They should be monitored and 
calibrated periodically and they must be submitted to 
preventive maintenance. If you want to fulfill the GMP 
requirements for quality assurance of products, you must 
consider several factors such as infrastructure, equipments 
and raw materials. Make sure that the whole production 
process is controlled until the final product is released. 
Since all the three processes, validation, calibration and 
qualification, are extremely critical in pharmaceutical 
processes, you must ensure that you have the right 
outsourcing partner to conduct them. When you have the 
correct partner by your side, you get vital assistance in 
maintaining GMP standards, while keeping the costs down. 
Look for important traits while choosing a partner, such as 
their quality management system, their ability meet all 
your requirements while containing the costs, response to 
fluctuating workloads, etc. Make sure you tie up with the 
partner who is right for your company, and there will be 
one less thing that you have to worry about. 
To make sure that validation of processes is legitimate, you 
have to do calibration. It is a process which demonstrates 
that an instrument is producing results within the specified 
limits as compared to those produced by a traceable 
standard over an appropriate range of measurements. It is 
extremely crucial that all calibration activities are 
performed with qualified instruments by an accredited 
laboratory. You must ensure that you always use calibrated 
instruments in manufacturing. Using uncalibrated 
instruments can lead to safety risks, which is an absolute 
no-no for any pharmaceutical company. You will see an 
increase in waste if you use uncalibrated instruments. 
Further, equipment of poor quality will cost you a lot of 
money too, putting a financial burden on your company. 
Calibrate your equipment periodically to ensure that the 
measurements and outputs achieved are accurate at all 
times without affecting the quality of the final product.9-11 
GOOD AUTOMATED MANUFACTURING PRACTICE 
(GAMP) 
GAMP stands for Good Automated Manufacturing Practice. 
Usually when one hears the terms GAMP, it is in reference 
to a guidance document entitled GAMP-5: A Risk-Based 
Approach to Compliant GxP Computerized Systems.  
GAMP-5's approach can be summed up by the V-model 
diagram in the beginning, or at least in GAMP 4, there were 
five categories of software:  
 Category 1: Operating systems 
 Category 2: Firmware 
 Category 3: Standard software  
 Category 4: Configured software  
 Category 5: Custom software 
 There was always a debate about some commercial 
software packages were they category 3 or 4? Many 
spectroscopists would argue that an application should be 
classified as category 3 and not 4, as it should be less work 
to validate and evade the real classification. To help resolve 
this debate, in GAMP 5 the software categories have been 
revised and refined most for the better and one for the 
worse. This is a natural evolution of this approach to 
software classification. So, we now have the following four 
categories:  
 Category 1: Infrastructure Software  
 Category 3: Nonconfigured products 
 Category 4: Configured products 
 Category 5: Custom applications  
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Why Classify Software: Before we go into a detailed 
discussion of the software categories, perhaps we should 
ask the question "Why bother to classify software?". What 
benefit does this software classification provide?  If you 
look at Table I there is a built-in risk assessment. The least 
risky and most widely available software is in category 1 
(operating systems, databases, office software, and other 
widely available software). This is widely available 
software that can be used by anyone and in any industry. 
As we progress through down the categories as shown in 
Table I, generally the software becomes more specialized 
in its function (from a general office application to 
software that can control a spectrometer to acquire and 
process data then report the results). As we go down the 
list there is the increasing ability of the users to change the 
operation of software and process the results until we 
reach category 5. In category 5 is a unique solution that is 
conceived, specified, written, tested, and maintained by the 
users or the organization; here is the greatest risk. Let's 
now take a detailed look at each of the software categories 
and see what has changed and if there are any problems 
we need to discuss.  
Software Classification Changes and Their Laboratory 
Impact: Presented and discussed here are the various 
changes to the software classifications in the new GAMP 
guide.  
Category 1: Greatly Expanded Scope-Infrastructure 
Software: Category 1 has undergone a radical change and 
expansion from simply operating systems, that had been 
constant in GAMP versions 1 to 4, to infrastructure 
software. This category is broken down into two 
subcategories:  
 Established or commercially available layered 
software and  
 Infrastructure software tools.  
The intention is that the infrastructure software in this 
category provides the computing environment for running 
both regulated and nonregulated applications within an 
organization. All software in this category needs to be 
controlled and qualified in an organization so that dual 
standards are not applied by the IT department, which can 
question the status of validated applications if not done. 
Software in the subcategory of Established or 
Commercially Available Layered Software still includes 
operating systems from GAMP 4, but this has also been 
expanded to encompass a greater scope:  
 databases  
 programming languages  
 middleware  
 office software 
 ladder logic interpreters (for manufacturing systems),  
 Statistical programming tools and spreadsheet 
packages.  
The key issue is that many of these software tools are the 
base products for the applications used in the laboratory or 
they are the foundation layer for the laboratory 
applications to operate under. For example, if your 
spectrometer has application software that has a database 
to manage the methods, data, and results you generate, the 
latter is configured by the spectrometer supplier from the 
out-of-the-box database to operate with their application 
software. Languages are used as a means to write the 
applications, each of which will be validated for their 
intended use. Note that category 1 also includes office 
software such as word processing, spreadsheet, database, 
and presentation applications. Now before you rush off 
thinking that Excel templates and macros do not need to be 
validated, think again, as the guide notes that "applications 
developed using these packages" are excluded from 
category 1 and these can be category 3, 4, or 5, 
respectively, depending on their complexity. Note also the 
phrasing of the subcategory "established or commercially 
available". This means that both open source and software 
commercial can be used, which ratifies the status quo 
(open source operating systems [Linux or OpenVMS], 
databases [MySQL], and source code management [Sub 
Version]). In many IT departments and research groups 
open source software is used and often this use can be 
extensive. Some people may argue that open source 
software is hacked code, but when the code can be 
reviewed by many programmers it may be argued that the 
quality of the finished application could be better than 
some commercially available software. Regardless of the 
debate, the word established allows the use of open source 
applications within category 1.  
Software Categories 3, 4, and 5: A Quick Reprise: GAMP 
version 5 has defined these three software categories as 
follows:  
 Category 3: Nonconfigured Products: Off-the-shelf 
products that cannot be changed to match the business 
processes but this category also can include 
configurable software products but where only the 
default configuration is used.  
 Category 4: Configured Products: Configured 
software products provide standard interfaces and 
functions that enable configuration of the application to 
meet user-specific business processes. However, 
configuration using a vendor-supplied scripting 
language should be handled as custom components 
(category 5). 
 Category 5: Custom Applications: These applications 
are developed to meet the specific needs of a regulated 
company. This definition implicitly includes 
spreadsheet macros written using visual basic for 
applications (VBA) and LIMS language customizations. 
It also will include macros written for some 
spectroscopy software as short cuts for performing a 
series of tasks. Note that this is the highest risk 
software, as there is the greatest likelihood of 
functional omissions, bugs, and errors in the software, 
and therefore, the life cycle model used needs to have 
sufficient controls to ensure that it is properly 
specified, designed, built, and tested before release. 
GAMP 5 notes that these categories are not silos of 
software but a continuum: There might be elements of a 
higher or lower category depending how the software is 
used and/or configured or customized.  
Importance of System Life Cycle Model: A software 
application or a computerized system does not suddenly 
materialize out of thin air. Each one needs to be planned 
and implemented. Therefore, the use of a system life cycle 
is important as it provides a plan to use as a basis for the 
implementation or building of a computerized system. 
Note the words:  
 Plan: A plan is a blue print or road map for carrying out 
a task. It will outline the stages or phases that need to 
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be gone through so that the system will be built 
correctly and function as required.  
 Basis: Plans can be changed to fit the system that is 
being implemented or developed and you should 
accept that there is no one-size-fits-all approach. A 
specific system can have more, the same, or fewer 
needs than the standard life cycle model will provide 
and therefore, adaptation of the plan might be needed 
to accommodate them.  
Therefore, the key requirement of any life cycle model 
used is that it should be meaningful and applicable to the 
system that you are building or implementing. If it is not, 
then you have problems. 
CSV is interlinked very closely with the software 
development life cycle (SDLC) considering that it is 
conducted at every stage of SDLC. CSV forms part of the 
testing process with one key differentiation of validation at 
each step, instead of a single final stage testing. The CSV 
process is in fact created keeping in view the steps of the 
SDLC, and is roughly modelled as per an archaic model of 
the same. The entire process of computer system 
validation is created keeping in mind the FDA guidelines 
that have been defined for pharma, in order to meet the 
quality standards and adhere to the pharmaceutical cGMP. 
So in a lot of ways, it is the FDA guidelines which have 
created the framework for CSV and continue to define the 
way it’s shaped and remodeled over time, depending on 
the dynamic factors in the pharmaceutical industry 12-13. 
PROCESSES NEEDED FOR COMPUTER SYSTEM 
VALIDATION 
Qualification activities should be described in a master 
plan. The plan documents a company’s approach for 
specific activities, for example, how to qualify analytical 
instruments, how to assess vendors or what to test for 
commercial computer systems. A master plan serves two 
purposes: when implemented right, it ensures consistent 
and efficient implementation of equipment qualifications, 
and it answers an inspector’s question for a company’s 
approach for instrument qualification and system 
validation. A validation master plan is also officially 
required by Annex 15 to the European GMP directive: “All 
validation activities should be planned. The key elements 
of a validation program should be clearly defined and 
documented in a Validation Master Plan (VMP) or 
equivalent documents”. FDA regulations and guidelines do 
not specifically require a validation master plan. However, 
inspectors want to know what the company’s approach 
towards validation is. The qualification master plan is an 
ideal tool to communicate this approach both internally 
and to inspectors. In case there are any questions as to why 
things have been done or not done, the master plan should 
provide the answers. CSV is dependent on the complexity 
of the project and can be largely broken down into the 
following processes: 
Master Plan: This checks whether the specifications are in 
line with user requirements. During this stage, teams are 
also established which will run the entire process. The set 
of activities to be carried out during validation are 
established too. This is basically the process of preparing 
the blueprint for the entire CSV. This process is the pivot of 
a validation program since it covers the complete setup 
such as the physical hardware, software, sites and also 
validates processes such as risk mitigation and redundancy 
strategies. Equipment and computer validation master 
plans should include: 
1. Introduction with a scope of the plan, e.g., sites, systems, 
processes 
2. Responsibilities, e.g., user departments, QA, IT 
3. Related documents, e.g., risk master plan 
4. Products/processes to be validated and/or qualified 
5. Qualification/validation approach 
6. Risk assessment 
7. Steps for equipment qualification and computer system 
validation with examples on type and extent of testing 
8. Vendor assessment 
9. Handling existing systems 
10. Change Control procedures and templates 
11. Instrument obsolescence and removal 
12. Training plans (system operation, GMP) 
13. Templates and references to SOPs 
14. Glossary 
Project Plan: The project plan outlines what is to be done 
in order to get a specific system into compliance. For 
inspectors, it is a first indication of the control a laboratory 
has over a specific instrument or system and it also gives a 
first impression of the qualification quality. This process 
defines the standard operating procedures for each 
process in a validation assessment program and is a subset 
of the master validation plan. More importantly it defines a 
deadline within which the CSV must be completed. A 
detailed documentation and training on the standard 
operating procedures (SOPs) is carried out during this 
process. Additionally activities such as risk assessment, 
backup planning and change management are also 
undertaken during this phase. If a master plan is defining 
the outline, then a project plan is the execution stage. 
Figure 1 shows the link between the master plan and 
project plan. Ideally master plans are developed at a 
corporate level. Project plans are written in departments 
specifically for an instrument or system. Depending on the 
size, structure and geographic distribution there also may 
be a site or country specific master plan that is derived 
from the corporate master plan but has been customized 
according to specific circumstances and requirements of 
that site. 
 
Figure 1: Link between master plan and project plan. 
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Design Qualification: “Design qualification (DQ) is the 
documented collection of activities that define the 
functional and operational specifications of the instrument 
and criteria for selection of the vendor, based on the 
intended purpose of the instrument. Design qualification is 
a shared responsibility between the vendor and the user of 
an instrument. 
Requirement specifications: Requirement specifications 
of software and computer systems should be linked to test 
cases in some kind of traceability matrix. This can be a 
table on its own or the link can be built into the 
requirements table. Each specification should have a 
unique ID code. Criticality of the function can be defined as 
high, medium or low. Most important questions to ask are: 
what happens if the function does not work at all or if it 
produces wrong results? In the next column the test 
priority is documented. Criticality plays a major role but 
also the question as to how the user’s environment or the 
user, for example through a wrong user configuration, can 
influence correct functioning. 
Installation Qualification (IQ): This stage delves deeper 
into the installation process and creates checks and 
balances for any new component that may have been 
purchased (such as new IT equipment) or any new 
software or hardware that may have been installed. Tasks 
performed for IQ include: 
 Prepare the laboratory facility according to vendor 
environmental specifications. 
 Control and record environmental conditions, if 
critical. For example, temperature and humidity. 
 Compare equipment received with the purchase order 
(including, accessories and spare parts). 
 Check equipment for any damage. 
 Verify that the instrument conforms with physical and 
construction requirements, as specified by the user. 
 Check documentation for completeness (operating 
manuals, maintenance instructions, standard 
operating procedures for testing, safety and validation 
certificates). 
 Install hardware (instrument, fittings and tubing for 
fluid connections, columns in HPLC and GC, power 
cables, data flow and instrument control cables). 
 Switch on the instruments and ensure that all modules 
power up and perform an electronic self-test. 
 List equipment manuals and SOPs. 
 Record firmware revision. 
 Prepare an installation report. 
 Enter instrument data into an inventory data base. 
 Prepare, review and sign formal IQ documentation. 
Operational Qualification (OQ): “Operational 
qualification (OQ) is the documented collection of activities 
necessary to demonstrate that an instrument will function 
according to its operational specification in the selected 
environment “Emphasis should be placed on “in the 
selected environment”. Testing of instrument hardware at 
the user’s site is required because instrument 
characteristics can change when shipped from the vendor 
to the user, for example through mechanical vibration. The 
most frequently asked questions related to OQ testing are: 
what should be tested, which are the acceptance criteria, 
and who should perform the tests? USP answers all the 
questions in a single sentence: “Users, or their qualified 
designees, should perform these tests to verify that the 
instrument meets manufacturer or user specifications in 
the user’s environment. Designees could be, for example, 
vendor representatives.” 
The frequency of OQ depends on the type of instrument, on 
the stability of the performance characteristics, but also on 
the specified acceptance criteria. In general, the time 
intervals should be selected so that the probability is high 
that all parameters are still within the operational 
specifications. Otherwise, analytical results obtained with 
that particular instrument are questionable. Here the 
importance of proper selection of the procedures and 
acceptance limits becomes very apparent. For example, if 
the baseline noise of a UV/Visible detector is set to the 
lowest possible limit as specified by the vendor, the lamp 
will have to be changed more frequently than when set at a 
factor of 5 higher. 
Performance/Process Qualification (PQ): PQ tests 
specific applications and proactively engages in 
maintenance and conducts performance tests. All the 
processes contribute to effectively meeting pharmaceutical 
cGMP and help ensure that all the technical systems 
involved are contributing to help meet the required 
product quality standards. 
Configuration Management and Change Control:  The 
purpose of configuration management is to be aware of the 
lifetime composition of the system from planning to 
retirement. The initial or baseline configuration of a 
system has been documented as part of IQ. Any changes to 
specifications, programming codes or the initial set up of 
computer hardware should follow written change control 
procedures and be documented. Changes may be initiated 
because errors have been found in the program or because 
additional or different software functions or hardware may 
be desirable. Requests for changes should be submitted by 
users and authorized by the user’s supervisor or 
department manager 14-15. 
21 CFR Part 11 – FDA’s Regulation on Electronic 
Records and Signatures: In 1997 the United States Food 
and Drug Administration (FDA) issued a regulation that 
provides criteria for acceptance by the FDA of electronic 
records, electronic signatures and handwritten 
signatures21. With this regulation, entitled Rule 21 CFR 
Part 11, electronic records can be equivalent to paper 
records and handwritten signatures. The rule applies to all 
industry segments regulated by the FDA that includes 
Good Laboratory Practice (GLP), Good Clinical Practice 
(GCP) and current Good Manufacturing Practice (cGMP). 
Part 11 requires computer systems used in FDA regulated 
environments to be validated. Chapter 10 (a) states: 
Computer systems should be validated to ensure accuracy, 
reliability and consistent intended performance. There is 
no further instruction on how computer systems should be 
validated 16-17. 
Validation Report: At the end of validation, a summary 
report should be developed. This should be a mirror of the 
validation project plan. It should be organized in such a 
way that it has all the elements and follows the outline of 
the validation plan. This makes it easy to check if all plan 
items have been completed successfully. Deviations should 
be documented, if there are any, together with corrective 
actions and/or work around solutions. The report should 
include a statement that the instrument or system is 
qualified or validated. After the statement and the report 
have been signed by management, the product can be 
released for operation. Typically, the validation plan and 
the report are the first documents inspectors want to see 
when they inspect a validation project. If everything is well 
organized and documented, it may well be that after 
looking at both documents inspectors get such a good 
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impression about the validation work that they will focus 
on other inspection areas. 
COMMON COMPUTER SYSTEM VALIDATION 
PROBLEMS 
Computer System Validation (CSV) in the life sciences was 
focused on software validation and infrastructure and 
computing platform qualification for systems that 
supported FDA-regulated activities and records. Today, 
organizations are increasingly focusing on overall, global 
IT compliance, to satisfy 21 CFR Part 11 but also equivalent 
laws in other countries, Sarbanes-Oxley (SOx), HIPAA, 
export and shipping regulations, and much more. To meet 
these varied and global needs, pharmaceutical 
manufacturers must: 
Challenge I. Standards: Various standards exist across the 
organization. Policies, procedures, work instructions, and 
templates vary by business, department, or site. Significant 
costs result from overlapping SOPs and inconsistent 
standards, which make sharing of assets difficult. Industry-
wide standard methodologies, guidelines, and tools have 
been issued by global organizations, such as ISPE and ICH, 
but in order to make the assets applicable to a wide range 
of companies, processes, systems, and products, they did 
not replace the more detailed, localized standards. 
Challenge II. Interpretation: A significant cost to 
validation projects is caused by long debates among the 
various authors and reviewers, rework, and inconsistent 
interpretation of standards and requirements. Most 
regulations include very high-level statements that set 
objectives, but don’t specify how to implement the controls 
or how much is good enough. For example, 21 CFR Part 11 
(11.10 (d)) requires “Limiting system access to authorized 
individuals.” This one statement can be expanded to varied 
requirements for technical security controls and 
procedural controls for managing access. 
Challenge III. Organization and Governance: Many 
companies still have decentralized governance and 
uncontrolled execution. The ownership and management 
of validation activities vary from project to project and 
from one department to another. Projects are not handled 
consistently with clear roles and responsibilities. Some are 
led by IT, other by users or quality. 
Challenge IV. Efficiency Across Sites and Departments: 
Site-to-site efficiencies have not been achieved due to site- 
and department-specific procedures, templates, and 
interpretation. We’ve seen many cases where multiple 
sites develop complete validation packages for the same 
system that they use the same way, because there is no 
sharing of inventory and project information. 
Challenge V. Execution: As stated earlier, we see 
excessive rework being done by validation teams. Most 
often, the rework is a result of different opinions and styles 
of project team members and inconsistent quality of work 
that is done by unqualified individuals. A common scenario 
is that individuals perform work that doesn’t align with 
their level and skills. Junior quality reviewers, who are 
qualified to review documents and identify incomplete or 
inaccurate information and deviations from standards, end 
up determining the course of action to remediate the 
problems. The solution is often redoing the work. On the 
other hand, we see highly-qualified, expensive resources 
performing low-level mechanical tasks, because a fixed 
team is assigned to the project and must share the 
workload. 
Challenge VI. Tools: System life cycle assets, such as 
templates, outlines, forms, and guidance documents are 
often inconsistent across departments and are not targeted 
to drive value. They are put in place to minimize the risk of 
project team members taking shortcuts and skipping 
sections, but are not flexible and drive unnecessary efforts 
with minimal value to quality or compliance. We’ve seen 
cases where an extensive validation package was prepared 
for a new CD writer, or complete detailed Installation 
Qualification protocol, scripts, and report were produced 
for the installation of utilities such as WinZip and virus 
scan. 
Challenge VII. Training: Training is usually conducted 
within each business on standards and processes; 
however, there is minimal coaching and guidance. The 
short training that is usually provided is rarely enough to 
qualify individuals without coaching and support until they 
gain hands-on experience. Often multiple training sessions 
have to be taken in a very short period of time, where the 
individual’s ability to absorb, understand and retain the 
materials is in question. 
Challenge VIII. Personnel: Working with many life 
science companies shows that usually there are capable, 
knowledgeable central validation groups, but weaker 
decentralized execution groups. CSV standards are often 
deployed without the appropriate training and coaching 
and without assurance of consistent interpretation. 
Organizations believe that simply reading standard 
operating procedures (SOPs) and receiving a few hours of 
training enable individuals to follow a consistent 
approach18-23. 
COMMON FDA OBSERVATIONS THAT CAN BE 
AVOIDED WITH GOOD CSV PRACTICES 
Failure to Validate a Regulated System: Validation 
activities and the documentation generated during these 
activities are often an area of interest for inspectors. In the 
case of Computer System Validation, an inspector would 
typically look for documented evidence that validation 
activities were performed in accordance with approved 
validation procedures. Additionally, the documentation 
presented to the inspectors should show that applicable 
regulatory requirements were met. 
Absence of Written Procedures:  Procedures provide an 
established, approved framework for carrying out tasks 
within a regulated environment. And they are often among 
the first documents requested by inspectors. Validation 
procedures should document with sufficient detail how 
validation activities are performed and what deliverables 
are generated via these activities. The approach to 
validation taken should also be specified. Ensure that the 
approach takes into account applicable regulations (such 
as 21 CFR Part 11) and outlines the methodology used (for 
example, a risk-based approach following GAMP 5). 
Moreover, the process stakeholders should be identified 
and their respective roles and responsibilities should be 
clearly defined.  
Written Procedures Not Followed: When performing 
computer system validation, make sure that any deviations 
to the validation plan are documented and a rationale for 
the deviation is provided. Validation non-conformances 
should be addressed by identifying the root cause and 
implementing appropriate corrective actions. The system 
must not be released for use prior to completing validation 
and any system limitations should be specified in writing. 
Changes made to the system once it is validated should be 
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put in place in accordance with an approved change 
request.  
Failure to Maintain Records: Computer systems are used 
to manage a variety of regulated documents, ranging from 
training records and complaint files to raw data obtained 
during laboratory and production activities. Failure to 
demonstrate during validation that a regulated computer 
system functions as intended can lead to serious problems 
and potential regulatory observations down the line. Data 
integrity and security could be compromised, resulting in 
the inability to produce documentation requested during 
inspections. If a computer system is used to track reporting 
to regulatory bodies, such as the mandatory reporting of 
medical device issues or adverse drug experiences, it is 
crucial to ensure that the system performs as expected to 
be sure that reporting deadlines are respected24-29.  
CONCLUSION 
Pharmaceutical manufacturers can definitely improve their 
validation projects by performing several measures to 
minimize or eliminate the deficiencies in the computer 
system validation problems discussed above. 
Collaboration, prioritization, planning, oversight, and 
clarity of purpose can also substantially promote the 
success of validation projects. Research study on the 
existing validation frameworks should be carried out to 
identify possible positive elements which may help to 
eliminate most of the pitfalls discussed in this paper. These 
elements can be incorporated in a framework which fulfills 
the basic framework design requirements. It must be 
simple, systematic, can easily be understood by the future 
implementers and flexible enough to adapt itself to 
different contexts. This framework must be validated by 
applying it in case studies which must be carried out in 
pharmaceutical companies to confirm its flexibility, 
robustness and validity. In order to achieve it, it is 
suggested that these case studies should be conducted in 
three different backgrounds in a pharmaceutical company 
to validate facilities, utility systems and equipments. The 
possible application of this new validation framework into 
the existing validation procedure can help future 
implementers to achieve remarkable improvements in 
validation scope, thus significantly saving manufacturers’ 
time, effort, and money invested in validation projects. 
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